Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
About this item
Full title
Author / Creator
Publisher
London: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Hepatocellular carcinoma (HCC) is a fatal disease with rising incidence in the world. For advanced HCC, sorafenib, a multikinase inhibitor, is the only systemic therapy with proven survival benefits. Sorafenib is a pan-VEGF receptor inhibitor, and thus many studies have focused its antivascular effects. But VEGF also acts as an immunosuppressive mo...
Alternative Titles
Full title
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5619018
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5619018
Other Identifiers
ISSN
1750-743X
E-ISSN
1750-7448
DOI
10.2217/imt.15.126
